12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ProstaScint iII-indium capromab pendetide diagnostic data

In a 10-year patient outcomes study in 239 patients who underwent permanent prostate brachytherapy using ProstaScint imaging in combination with CT scans, bDFS was 93.5% for low-risk patients (n=116), 86.9% for intermediate-risk patients (n=72)...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >